Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure

The Lancet Infectious Diseases, Год журнала: 2023, Номер 24(2), С. e70 - e72

Опубликована: Дек. 15, 2023

The SARS-CoV-2 saltation variant BA.2.86, which was quickly designated as a under monitoring after its emergence, has garnered global attention. Although BA.2.86 did not show substantial humoral immune escape and growth advantage compared with current dominant variants, such EG.5.1 HK.3, it showed remarkably high ACE2 binding affinity.1Yang S Yu Y Jian F et al.Antigenicity infectivity characterisation of BA.2.86.Lancet Infect Dis. 2023; 23: e457-e459Summary Full Text PDF PubMed Scopus (36) Google Scholar, 2Wannigama DL Amarasiri M Phattharapornjaroen P al.Tracing the new in community through wastewater surveillance Bangkok, Thailand.Lancet e464-e466Summary (11) 3Wang Q Guo Liu L receptor affinity spike.Nature. (published online Oct 23.)https://doi.org/10.1038/s41586-023-06750-wGoogle 4Uriu K Ito J Kosugi al.Transmissibility, infectivity, evasion variant.Lancet e460-e461Summary (29) 5Sheward DJ Yang Westerberg al.Sensitivity to prevailing neutralising antibody responses.Lancet e462-e463Summary (22) Scholar This increased affinity, coupled distinct antigenicity, could enable accumulate immune-evasive mutations during low-level populational transmission, akin previous evolution from BA.2.75 CH.1.1 XBB.6Cao Song W Wang al.Characterization enhanced Omicron BA.2.75.Cell Host Microbe. 2022; 30: 1527-1539Summary (74) 7Cao al.Imprinted immunity induces convergent RBD domain evolution.Nature. 614: 521-529PubMed 8Yue C al.ACE2 transmissibility XBB.1.5.Lancet 278-280Summary (108) 9Wang Li Z al.Evolving sublineage SARS-CoV-2.iScience. 26108254 Summary (3) With just one additional mutation (L455S) predecessor JN.1 rapidly became predominant France (figure A; appendix 1 p 12), surpassing both so-called FLip (L455F+F456L) strains. A thorough investigation into capability JN.1, particularly given few mutations, is imperative.FigureJN.1 shows profound decreased affinityShow full caption(A) Sequence percentages prevalent variants since August, 2023, including BA.2·86 (the original subvariants, except JN.1), HV.1, FLip+A475V, HK.3. advantages relative HK.3 past two months these strains are denoted legend within parentheses. Data collected covSPECTRUM. (B) 50% titer (NT50) convalescent plasma against measured individuals who received three CoronaVac doses had breakthrough infection BA.5 or BF.7 followed by XBB reinfection (n=54). Labels for geometric mean titers (GMT) located above each group, fold changes statistical significances indicated GMT labels. Below dashed line labels specifying numbers negative samples related limit detection (NT50=20). Two-tailed Wilcoxon signed-rank tests paired were used. *p<0·05, **p<0·01, ***p<0·001, ****p<0·0001. (C) human (angiotensin-converting enzyme 2) affinities (XBB.1.5+L455F+F456L), HV.1 (XBB.1.5+L452R+F456L), EG.5 (XBB.1.5+F456L), JD.1.1 (XBB.1.5+L455F+F456L+A475V), (BA.2.86+L455S) determined surface plasmon resonance sensorgrams. KD values (nM) displayed bars, all replicates represented points. (D) Class Nabs resistance pseudovirus XBB.1.5, EG.5, JD.1.1, IC50 (n=8). when D614G other labelled. (μg per mL) approved candidate monoclonal drugs targeting spike assessed pseudovirus. IC50=50% inhibitory concentration; KD=equilibrium dissociation constant; NAbs=neutralising antibodies; nM=nanomolarView Large Image Figure ViewerDownload Hi-res image Download (PPT) (A) nM=nanomolar We first study using pseudovirus-based neutralisation assays recovering infection. These individuals, having inactivated vaccines, subsequently contracted (XBB subvariants S486P substitution) infections. Our included cohorts, 27 participants post-vaccination infections another patients reinfected (appendix 2). significantly B). finding evidenced 2·1-fold decrease among post-BA.5 1·1-fold NT50 B; 13). Additionally, JN.1's surpassed that competitive (EG.5+L452R) (FLip+A475V). also lower their parental acquiring L452R A475V respectively, explaining advantages. As L455 on interface between 14),10Nutalai R Zhou D Tuekprakhon al.Potent cross-reactive antibodies following vaccinees.Cell. 185 (31.e18): 2116Summary (76) L455S change JN.1. By resonance, we found notable reduction domain, indicating capabilities come at expense reduced C). carried (XBB.1.5+FLip+A475V) resulted enhancing (XBB.1.5+FLip). However, affect affinity. Considering predominantly epitope antibodies, earlier research, our further examined response eight XBB.1·5-neutralising class antibodies.7Cao Pseudovirus addition ability evade D). effectively compensated BA.2.86's susceptibility this group Similarly, FLip+A475V (JD.1.1) (HK.3), offering insights trend variants. In terms therapeutic SA55 retained efficacy E). Together, findings suggest greatly compensation weakness antibodies. summary, inheriting antigenic diversity acquisition L455S, achieved extensive across 1, 2, 3 antibodies,1Yang higher resistant like JD.1·1, binding. evolutionary pattern, similar transition XBB,2Wannigama highlights importance closely BA.2.75, despite unremarkable capabilities. Such survive transmit low levels difference would allow them target populations have potential highly cost publication been corrected. corrected version appeared thelancet.com/infection January 3, 2024 YC inventor provisional patent applications BD series includes BD55–5514 (SA55). founder Singlomics Biopharmaceuticals. All authors declare no competing interests. .pdf (3.2 MB) Help pdf files Supplementary .xls (.02 xls 2 Correction Lancet Dis published Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2Yang S, Y, Xu al. Fast heavy pressure. https://doi.org/10.1016/S1473-3099(23)00744-2—In Correspondence, author's name should printed Yunlong Cao. corresponding email address read [email protected]. corrections made Jan 2024. Full-Text

Язык: Английский

---

Virological characteristics of the SARS-CoV-2 JN.1 variant

The Lancet Infectious Diseases, Год журнала: 2024, Номер 24(2), С. e82 - e82

Опубликована: Янв. 3, 2024

Язык: Английский

---

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Март 13, 2024

Abstract The unceasing circulation of SARS-CoV-2 leads to the continuous emergence novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 JN.1 variants, representing >80% circulating variants in January 2024. XBB subvariants carry few but recurrent mutations spike, whereas harbor >30 additional changes. These replicate IGROV-1 no longer Vero E6 are not markedly fusogenic. They potently infect nasal epithelial cells, with EG.5.1.3 exhibiting highest fitness. Antivirals remain active. Neutralizing antibody (NAb) responses from vaccinees BA.1/BA.2-infected individuals lower compared BA.1, without major differences between variants. An breakthrough infection enhances NAb against both BA.2.86 displays affinity ACE2 higher immune evasion properties BA.2.86.1. Thus, while distinct, evolutionary trajectory these combines increased fitness evasion.

Язык: Английский

---

XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1

Cell Host & Microbe, Год журнала: 2024, Номер 32(3), С. 315 - 321.e3

Опубликована: Фев. 19, 2024

COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of SARS-CoV-2 XBB.1.5 subvariant, but their immunogenicity in humans has yet be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report administration an monovalent mRNA vaccine booster (XBB.1.5 MV) previously uninfected individuals boosted serum virus-neutralizing antibodies significantly not only (27.0-fold increase) EG.5.1 (27.6-fold also key emerging such as HV.1, HK.3, JD.1.1, JN.1 (13.3- 27.4-fold increase). Individuals infected by Omicron subvariant had highest overall neutralizing titers (ID

Язык: Английский

---

Neutralization escape by SARS-CoV-2 Omicron subvariant BA.2.86

Vaccine, Год журнала: 2023, Номер 41(47), С. 6904 - 6909

Опубликована: Окт. 21, 2023

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variant BA.2.86 has over 30 mutations in spike compared with BA.2 and XBB.1.5, which raised the possibility that might evade neutralizing antibodies (NAbs) induced by vaccination or infection. In this study, we show NAb titers are substantially lower to but similar slightly higher than other current circulating variants, including EG.5.1, FL.1.5.1. Moreover, against all these variants were vaccinated individuals a history of XBB.1.5 infection no infection, suggesting potential utility monovalent mRNA boosters.

Язык: Английский

---

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency

Cell, Год журнала: 2024, Номер 187(3), С. 596 - 608.e17

Опубликована: Янв. 8, 2024

Язык: Английский

---

Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Дек. 6, 2023

Abstract Omicron BA.2.86 subvariant differs from BA.2 as well recently circulating variants by over 30 mutations in the spike protein alone. Here we report on isolation of live a diagnostic swab collected South Africa which tested for escape neutralizing antibodies and viral replication properties cell culture. We found that does not have significantly more relative to XBB.1.5 immunity elicited either XBB-family infection or residual sera African population. extensive ancestral virus with D614G substitution (B.1 lineage) when neutralized pre-Omicron vaccinated individuals BA.1 infected individuals. show similar dynamics VeroE6-TMPRSS2 H1299-ACE2 lines. also investigate relationship sequences. The closest sequences are samples Southern early 2022. Similarly, many basal were sampled Africa. This suggests potentially evolved this region, unobserved evolution led scale strains SARS-CoV-2.

Язык: Английский

---

Virological characteristics of the SARS-CoV-2 BA.2.86 variant

Cell Host & Microbe, Год журнала: 2024, Номер 32(2), С. 170 - 180.e12

Опубликована: Янв. 26, 2024

In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct lineage, the BA.2.86 variant, also emerged. is phylogenetically from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined virological characteristics of variant. Our epidemic dynamics modeling suggested that relative reproduction number significantly higher than EG.5.1. Additionally, four clinically available antivirals effective against BA.2.86. Although fusogenicity similar to parental BA.2 spike, intrinsic pathogenicity hamsters was lower BA.2. Since growth kinetics are those both vitro and vivo, attenuated likely due decreased replication capacity. These findings uncover features BA.2.86, providing insights for control treatment.

Язык: Английский

---

Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans

Immunity, Год журнала: 2024, Номер 57(4), С. 904 - 911.e4

Опубликована: Март 14, 2024

Immune imprinting describes how the first exposure to a virus shapes immunological outcomes of subsequent exposures antigenically related strains. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron breakthrough infections and bivalent COVID-19 vaccination primarily recall cross-reactive memory B cells induced by prior Wuhan-Hu-1 spike mRNA rather than priming Omicron-specific naive cells. These findings indicate that immune occurs after repeated exposures, but whether it can be overcome remains unclear. To understand persistence imprinting, we investigated plasma antibody responses administration updated XBB.1.5 vaccine booster. We showed booster elicited neutralizing against current variants were dominated pre-existing previously spike. Therefore, persists multiple spikes through infection, including post vaccination, which will need considered guide future vaccination.

Язык: Английский

---

Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023

Eurosurveillance, Год журнала: 2024, Номер 29(2)

Опубликована: Янв. 11, 2024

Variant BA.2.86 and its descendant, JN.1, of SARS-CoV-2 are rising in incidence across Europe globally. We isolated recent BA.2.86, EG.5, XBB.1.5 earlier variants. tested live virus neutralisation sera taken September 2023 from vaccinated exposed healthy persons (n = 39). found clear escape against variants but no specific pronounced for or JN.1. Neutralisation corresponds to variant predominance may not be causative the upsurge JN.1 incidence.

Язык: Английский

---